Compare AstraZeneca plc (AZN) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Tyson Foods, Inc. — how do they compare? AstraZeneca plc trades at $158.06 (market cap $248.14B), while Tyson Foods, Inc. trades at $55.8 (market cap $19.85B). The key difference: AstraZeneca plc is far larger — about 12.5× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays the higher dividend (3.62%). Which is the better fit depends on your goals.
| AZN | TSN | |
|---|---|---|
Market Cap | $248.14B | $19.85B |
Sector | Health | Consumer Staples |
52-Week High | $209.48 | $68.75 |
52-Week Low | $147.06 | $50.72 |
Enterprise Value | $275.41B | $27.12B |
Dividend Yield | 2.01% | 3.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
Tyson Foods (TSN) trades at $57.16, down 1.52% on the day, amid a bearish technical signal. The company reported mixed Q3 2026 earnings, beating EPS estimates but missing revenue expectations, with beef segment losses weighing on results. Analyst consensus is a Buy with a $68.50 price target, but technical indicators show selling pressure. Recent news highlights debt tender offers and a maintained dividend, while cash flow trends show volatility.
The outlook is cautious; strong chicken and prepared foods segments provide stability, but persistent beef losses and volume declines pose near-term risks. Valuation metrics like P/E of 34.83 appear elevated relative to modest profitability, yet the stock trades below analyst targets, suggesting potential upside if operational challenges ease.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
